In this Review:
Tenofovir reduces perinatal HBV transmission risk
LDV/SOF+vedroprevir for 8 weeks: high SVR in cirrhotic GT1 HCV
Coffee intake improves noninvasive markers of liver disease
REP 2139 shows promise in chronic HBV/HDV co-infection
SOF+velpatasvir for 12 weeks: 99% SVR across HCV strains
Obeticholic acid: therapeutic benefit in PBC
SOF+daclatasvir: potent in GT3 HCV
Outcomes of hepatic decompensation in PBC
Vitamin E for NASH ± diabetes
Albumin resuscitation beneficial in sepsis-induced hypotension
Please login below to download this issue (PDF)